文献速递腹部技术与安全CT

增强CT定量分析鉴别高分化胰腺神经内分泌肿瘤与低分化神经内分泌癌

Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas.
PubMed 文献 · Eur Radiol · 2022-06-27

回顾性纳入17例胰腺神经内分泌癌(PNEC)和131例胰腺神经内分泌肿瘤(PNET)患者,分析增强CT定量参数。PNEC在动脉期和门脉期的绝对强化值、相对强化比值和强化比值均显著低于PNET(均p<0.001)。动脉期绝对强化和门脉期绝对强化是鉴别两者的独立因素,动脉期病灶强化诊断效能最高(AUC 0.922)。

要点

  • PNEC在动脉期和门脉期均表现为低血供,强化程度显著低于高分化PNET。
  • 动脉期绝对强化是鉴别PNEC与PNET的最佳定量参数,AUC为0.922。
  • 动脉期和门脉期绝对强化均为独立预测因子,OR均为0.96。

核心结论

  • 动脉期和门脉期绝对强化是鉴别PNET与PNEC的独立预测因子,诊断准确性良好;增强CT定量参数可区分PNEC与PNET。

研究设计与样本

  • 回顾性纳入经活检或手术证实的17例PNEC和131例PNET患者,收集一般人口学资料(性别、年龄)和CT定量参数(动脉期/门脉期绝对强化值、动脉期/门脉期相对强化比值、动脉期/门脉期强化比值),行单因素和多因素logistic回归分析,并生成ROC曲线评估各定量参数的诊断能力。

关键影像表现/征象

  • PNEC的动脉期和门脉期绝对强化值分别为19.5 ± 11.0和28.1 ± 15.8,PNET分别为78.8 ± 47.2和77.0 ± 39.4。
  • PNEC的动脉期和门脉期相对强化比值分别为0.57 ± 0.36和0.80 ± 0.52,PNET分别为2.03 ± 1.31和1.99 ± 1.13。
  • PNEC的动脉期和门脉期强化比值分别为0.62 ± 0.27和0.74 ± 0.19,PNET分别为1.22 ± 0.49和1.21 ± 0.36。
  • 上述定量参数在PNEC与PNET间差异均有统计学意义(均p < 0.001)。
  • PNEC表现为低血供,动脉期和门脉期增强CT衰减均显著低于高分化PNET。

诊断标准与关键数值

  • 多因素分析显示动脉期绝对强化为鉴别PNEC与PNET的独立因素,OR为0.96(95%CI:0.93,0.99)。
  • 多因素分析显示门脉期绝对强化为鉴别PNEC与PNET的独立因素,OR为0.96(95%CI:0.92,0.99)。
  • 动脉期病灶强化诊断效能最高,AUC为0.922(95%CI:0.867-0.960),门脉期绝对强化次之。

临床应用与阅片要点

  • 阅片时可关注动脉期和门脉期病灶的绝对强化值,PNEC的强化程度明显低于高分化PNET。
  • 动脉期病灶强化定量分析对鉴别PNEC与PNET具有较高诊断价值,可作为报告中的量化参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To identify quantitative CT features for distinguishing well-differentiated pancreatic neuroendocrine tumors (PNETs) from poorly differentiated pancreatic neuroendocrine carcinomas (PNECs).

MATERIALS AND METHODS: Seventeen patients with PNECs and 131 patients with PNETs confirmed by biopsy or surgery were retrospectively included. General demographic (sex, age) and CT quantitative parameters (arterial/portal absolute enhancement, arterial/portal relative enhancement ratio, arterial/portal enhancement ratio) were collected. Univariate and multivariate logistic regression analyses were performed to confirm independent variables for differentiating PNECs from PNETs. Receiver operating characteristic (ROC) curves for each quantitative parameter were generated to determine their diagnostic ability.

RESULTS: PNECs had a much lower mean arterial/portal absolute enhancement value (19.5 ± 11.0 vs. 78.8 ± 47.2; 28.1 ± 15.8 vs. 77.0 ± 39.4), arterial/portal relative enhancement ratio (0.57 ± 0.36 vs. 2.03 ± 1.31; 0.80 ± 0.52 vs. 1.99 ± 1.13), and arterial/portal enhancement ratio (0.62 ± 0.27 vs. 1.22 ± 0.49; 0.74 ± 0.19 vs. 1.21 ± 0.36) than PNETs (all p < 0.001). After multivariable analysis, arterial absolute enhancement (odds ratio [OR]: 0.96, 95% confidence interval [CI]: 0.93, 0.99) and portal absolute enhancement (OR: 0.96, 95% CI: 0.92, 0.99) were independent factors for differentiating PNECs from PNETs. For each quantitative parameter, arterial lesion enhancement yielded the highest diagnostic performance, with an area under the curve (AUC) of 0.922 (95% CI: 0.867-0.960), followed by portal absolute enhancement.

CONCLUSIONS: Arterial/portal absolute enhancements were independent predictors with good diagnostic accuracy for differentiating between PNETs and PNECs. Quantitative parameters of enhanced CT can distinguish PNECs from PNETs.

KEY POINTS: • PNECs were hypovascular and had a much lower enhanced CT attenuation in both arterial and portal phases than well-differentiated PNETs. • Quantitative parameters derived from enhanced CT can be used to distinguish PNECs from PNETs. • Arterial absolute enhancement and portal absolute enhancement were independent predictive factors for differentiating between PNETs and PNECs.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Chen, Pan, Chen, et al. Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas. Eur Radiol. 2022. PMID: 35759016. doi:10.1007/s00330-022-08891-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。